Single Turnover of Transient of Reactants Supports a Complex Interplay of Conformational States in the Mode of Action of <i>Mycobacterium tuberculosis</i> Enoyl Reductase

The enoyl reductase from <i>Mycobacterium tuberculosis</i> (<i>Mt</i>InhA) was shown to be a major target for isoniazid, the most prescribed first-line anti-tuberculosis agent. The <i>Mt</i>InhA (EC 1.3.1.9) protein catalyzes the hydride transfer from the 4<i&g...

Full description

Bibliographic Details
Published in:	Future Pharmacology
Main Authors:	Leonardo Kras Borges Martinelli, Mariane Rotta, Cristiano Valim Bizarro, Pablo Machado, Luiz Augusto Basso
Format:	Article
Language:	English
Published:	MDPI AG 2023-03-01
Subjects:	tuberculosis InhA enoyl reductase mycolic acids isoniazid drug target
Online Access:	https://www.mdpi.com/2673-9879/3/2/23

Similar Items

N-[2-(1H-Indol-3-yl)-1-(5-thioxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)ethyl]-4-methylbenzenesulfonamide
by: Nikil Purushotham, et al.
Published: (2018-07-01)

Towards a new tuberculosis drug: pyridomycin – nature's isoniazid
by: Ruben C. Hartkoorn, et al.
Published: (2012-09-01)

Change in prevalence and molecular characteristics of isoniazid-resistant tuberculosis over a 10-year period in China
by: Fengmin Huo, et al.
Published: (2019-08-01)

Navigating the Chemical Space of ENR Inhibitors: A Comprehensive Analysis
by: Vid Kuralt, et al.
Published: (2024-03-01)

Identification of Novel Inhibitor of Enoyl-Acyl Carrier Protein Reductase (InhA) Enzyme in <i>Mycobacterium tuberculosis</i> from Plant-Derived Metabolites: An In Silico Study
by: Kratika Singh, et al.
Published: (2022-08-01)

Design, Synthesis and Molecular Docking of Novel Acetophenone-1,2,3-Triazoles Containing Compounds as Potent Enoyl-Acyl Carrier Protein Reductase (InhA) Inhibitors
by: Fawzia Faleh Albelwi, et al.
Published: (2022-06-01)

Prevalence of katG and inhA mutations associated with isoniazid resistance in Mycobacterium tuberculosis clinical isolates in Cameroon
by: Vanessa Ninkeh Nono, et al.
Published: (2025-03-01)

Design and Synthesis of Highly Active Antimycobacterial Mutual Esters of 2-(2-Isonicotinoylhydrazineylidene)propanoic Acid
by: Václav Pflégr, et al.
Published: (2021-12-01)

In vitro modeling of isoniazid resistance mechanisms in Mycobacterium tuberculosis H37Rv
by: Thanadon Dokrungkoon, et al.
Published: (2023-07-01)

Comparative Modeling and Molecular Dynamics Simulation of Substrate Binding in Human Fatty Acid Synthase: Enoyl Reductase and β-Ketoacyl Reductase Catalytic Domains
by: Arun John, et al.
Published: (2015-03-01)

Functional characterization of triclosan-resistant enoyl-acyl-carrier protein reductase (FabV) in Pseudomonas aeruginosa
by: Yong-Heng Huang, et al.
Published: (2016-11-01)

The low enoyl-acyl carrier protein reductase activity of FabI2 is responsible for the high unsaturated fatty acid composition in Sinorhizobium meliloti
by: Ya-Hui Mao, et al.
Published: (2024-12-01)

Evaluation of High-Dose Isoniazid in Multidrug-Resistant Tuberculosis Treatment
by: Valentina Gerussi, et al.
Published: (2025-03-01)

Synthesis and Antimicrobial Activity Screening of Piperazines Bearing <i>N</i>,<i>N′</i>-Bis(1,3,4-thiadiazole) Moiety as Probable Enoyl-ACP Reductase Inhibitors
by: Alaa Z. Omar, et al.
Published: (2022-06-01)

Isoniazid resistance-conferring mutations are associated with highly variable phenotypic resistance
by: Senamile Lale Ngema, et al.
Published: (2023-12-01)

Back to the future: a new ‘old’ lead for tuberculosis
by: Gerard D. Wright
Published: (2012-09-01)

Imidazoquinoline Derivatives as Potential Inhibitors of InhA Enzyme and <i>Mycobacterium tuberculosis</i>
by: Pascal Hoffmann, et al.
Published: (2024-06-01)

Isoniazid resistance profile in rifampicin resistant Mycobacterium tuberculosis
by: Naomee Shareef, et al.
Published: (2023-09-01)

The CRISPR-dCas9 interference system suppresses inhA gene expression in Mycobacterium smegmatis
by: Nuntita Singpanomchai, et al.
Published: (2024-10-01)

In Vitro Antimycobacterial Activity and Physicochemical Characterization of Diaryl Ether Triclosan Analogues as Potential InhA Reductase Inhibitors
by: Tarek S. Ibrahim, et al.
Published: (2020-07-01)

PatA Regulates Isoniazid Resistance by Mediating Mycolic Acid Synthesis and Controls Biofilm Formation by Affecting Lipid Synthesis in Mycobacteria
by: Kun Wang, et al.
Published: (2023-06-01)

New InhA Inhibitors Based on Expanded Triclosan and <i>Di</i>-Triclosan Analogues to Develop a New Treatment for Tuberculosis
by: Sarentha Chetty, et al.
Published: (2021-04-01)

Identification of novel inhibitors targeting Mycobacterium abscessus InhA through virtual screening, docking, and molecular dynamic simulations
by: Munawar Abbas, et al.
Published: (2025-04-01)

Rational design and microwave-promoted synthesis of triclosan-based dimers: targeting InhA for anti-mycobacterial profiling
by: Shekhar, et al.
Published: (2024-10-01)

Investigations on mutations in katG gene and inhA promoter region associated with isoniazid resistance in the clinical isolates of mycobacterium tuberculosis from Tehran, Iran
by: Shahrzad Shafiei, et al.
Published: (2024-03-01)

Targeting the Heart of Mycobacterium: Advances in Anti-Tubercular Agents Disrupting Cell Wall Biosynthesis
by: Ahmad Diab, et al.
Published: (2025-01-01)

Role of long-chain acyl-CoAs in the regulation of mycolic acid biosynthesis in mycobacteria
by: Yi Ting Tsai, et al.
Published: (2017-01-01)

Improving Lipid Content in the Diatom <i>Phaeodactylum tricornutum</i> by the Knockdown of the Enoyl-CoA Hydratase Using CRISPR Interference
by: Wenfeng Guo, et al.
Published: (2024-09-01)

Inducing vulnerability to InhA inhibition restores isoniazid susceptibility in drug-resistant Mycobacterium tuberculosis
by: Gregory A. Harrison, et al.
Published: (2024-03-01)

Tailoring selective triclosan azo-adducts: Design, synthesis, and anti-mycobacterial evaluation
by: Shekhar, et al.
Published: (2023-11-01)

Antitubercular drugs for an old target: GSK693 as a promising InhA direct inhibitor
by: María Martínez-Hoyos, et al.
Published: (2016-06-01)

Mutations of rpoB, katG, inhA and ahp genes in rifampicin and isoniazid-resistant Mycobacterium tuberculosis in Kyrgyz Republic
by: Jainagul Isakova, et al.
Published: (2018-03-01)

Reprogramming of the Aurantinin Polyketide Assembly Line to Synthesize Auritriacids by Excising an Atypical Enoyl‐CoA Hydratase Domain
by: Dacheng Wang, et al.
Published: (2024-09-01)

Effective pragmatic approach of diagnosis of multidrug-resistant tuberculosis by high-resolution melt curve assay
by: Sanjay Singh Negi, et al.
Published: (2018-01-01)

Kecepatan Asetilasi Isoniazid Pada Masyarakat Kediri
by: Mulyadi Mulyadi
Published: (2007-04-01)

Redox Imbalance and Oxidative DNA Damage During Isoniazid Treatment of HIV-Associated Tuberculosis: A Clinical and Translational Pharmacokinetic Study
by: Isaac Zentner, et al.
Published: (2020-07-01)

Isoniazid Linked to Sulfonate Esters via Hydrazone Functionality: Design, Synthesis, and Evaluation of Antitubercular Activity
by: Ebru Koçak Aslan, et al.
Published: (2022-10-01)

Recent Advances in Anti-Tuberculosis Drug Discovery Based on Hydrazide–Hydrazone and Thiadiazole Derivatives Targeting InhA
by: Yoanna Teneva, et al.
Published: (2023-03-01)

Pharmacogenomic insights into tuberculosis treatment shows the NAT2 genetic variants linked to hepatotoxicity risk: a systematic review and meta-analysis
by: Rashmi Mahajan, et al.
Published: (2024-12-01)

Treatment outcomes among patients with isoniazid mono-resistant tuberculosis in Mumbai, India: A retrospective cohort study
by: Sumaiya Khan, et al.
Published: (2024-12-01)